Johnson & Johnson Launches SURGICEL® Granules in China Following National Medical Device Innovation Fast Track Approval

Johnson & Johnson’s First Product Approved via China’s Medical Device Innovation Fast Track Benefits More Patients in China

ShanghaiNovember 6, 2022PR Newswire -- Today, Johnson & Johnson Medical Technologies unveiled its globally leading new surgical hemostasis productSURGICEL^®(Surgicel) Agglomerated GranulesDebuted at the CIIE and announced its official launch. This product is China's first granular regenerated oxidized cellulose hemostatic product, which can be used in various types of surgical procedures. With its unique granular structure, it enhances intraoperative hemostatic efficiency, innovatively empowering surgeries to be more reliable and efficient, benefiting patients. This is also the first innovative medical device product approved via the "Green Channel" by Johnson & Johnson.

SURGICEL® (Surgicel) Agglomerated Particles Officially Launched in China to Benefit Patients

In August this year, SURGICEL^®(Surgicel) Accumulated particles have been approved by the National Medical Products Administration through the National Innovative Medical Device Fast Track. As a revolutionary new product in the Surgicel hemostasis family, it has won multiple international and domestic awards, including the 2022 Society for Biomaterials Technological Innovation and Development Award, the 2021 Edison Patent Award, the 2018 20th MDEA Medical Design Excellence Award, the Global Top 100 R&D Technology Award, and the Global Design Excellence Innovation Award.

New "Particle" Measurement for Hemostasis: SURGICEL® (Surgicel) Aggregation Particles Debut at CIIE

The inspiration for the innovative development of this product came from a hash brown.Global Chief Scientist of Johnson & Johnson Medical Technology, Ethicon BiosurgeryDr. Allen Y. Wang stated：“SURGICEL^®(The revolutionary granular structure of Surgicel Accumulata was inspired by eating hash browns near Johnson & Johnson’s headquarters — the shape of the hash browns led me to try using randomly shaped, tightly packed particles to innovate our hemostatic products.)

Senior Director of Johnson & Johnson Medical Technology's Ethicon Biosurgery Division, Chen Songxin, stated: "We are very pleased to bring the revolutionary and innovative hemostatic black technology to the CIIE. This is also SURGICEL^®(QuickClot) The debut of Accumulated Granules in mainland China. With its official launch, it will become the new 'particle' strength in our surgical hemostasis family. We will provide a more comprehensive and leading portfolio of hemostatic products, empowering clinical practices and benefiting patients."

Johnson & Johnson Medical Technology's Ethicon Biosurgery business is dedicated to providing comprehensive solutions for hemostasis, anti-adhesion, and anti-leakage in surgical procedures. At this year's CIIE, innovative products such as Surgicel Fibrillar, Surgicel Snow, absorbable hemostatic gelatin, and Interceed, an absorbable adhesion barrier film used in gynecological surgeries, were showcased. As a global leader in the healthcare industry, Johnson & Johnson Medical Technology will accelerate the introduction of more innovative medical solutions to better serve patients in China and contribute to "Healthy China."